NEW YORK, Oct. 2 – Young, private genomic companies in the US anxious about a constricting venture capital market can breathe easy.

Despite sharp drops in the stock market, a receding overall venture capital tide, and the economic uncertainty brought on by the terrorist assault on the US three weeks ago, industry analysts believe that the private equity environment for early-stage genomic companies remains robust, has been outperforming the overall VC market, and shows signs of growth in the new year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.